GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Retained Earnings

Vectus Biosystems (ASX:VBS) Retained Earnings : A$-36.81 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Vectus Biosystems's retained earnings for the quarter that ended in Dec. 2023 was A$-36.81 Mil.

Vectus Biosystems's quarterly retained earnings declined from Dec. 2022 (A$-34.32 Mil) to Jun. 2023 (A$-35.63 Mil) and declined from Jun. 2023 (A$-35.63 Mil) to Dec. 2023 (A$-36.81 Mil).

Vectus Biosystems's annual retained earnings declined from Jun. 2021 (A$-29.13 Mil) to Jun. 2022 (A$-32.18 Mil) and declined from Jun. 2022 (A$-32.18 Mil) to Jun. 2023 (A$-35.63 Mil).

Vectus Biosystems Retained Earnings Historical Data

The historical data trend for Vectus Biosystems's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Retained Earnings Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Retained Earnings
Get a 7-Day Free Trial -21.85 -24.84 -29.13 -32.18 -35.63

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.67 -32.18 -34.32 -35.63 -36.81

Vectus Biosystems Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Vectus Biosystems  (ASX:VBS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines